Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALGSNASDAQ:ATHENYSE:CHRONASDAQ:FGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$7.21+1.0%$6.18$3.18▼$46.80$44.05M2.69210,527 shs87,518 shsATHEAlterity Therapeutics$3.93+0.3%$4.16$1.00▼$5.87$34.86M0.8144,516 shs66,743 shsCHROChromocell Therapeutics$1.35+15.4%$1.15$0.45▼$3.80$8.91M3.27444,925 shs1.76 million shsFGENFibroGen$5.22-1.5%$7.38$4.50▼$38.25$21.10M0.8376,930 shs59,699 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics0.00%-4.50%+33.77%-12.61%-17.60%ATHEAlterity Therapeutics0.00%-7.09%-11.88%+15.90%+117.13%CHROChromocell Therapeutics0.00%+17.39%+45.88%-3.36%+2.27%FGENFibroGen0.00%-9.22%-32.93%-32.62%-76.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALGSAligos Therapeutics4.1723 of 5 stars3.53.00.04.82.71.70.0ATHEAlterity Therapeutics2.6638 of 5 stars3.35.00.00.02.21.70.0CHROChromocell Therapeutics0.4858 of 5 stars0.04.00.00.00.02.50.0FGENFibroGen4.2154 of 5 stars3.33.00.04.72.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALGSAligos Therapeutics 3.00Buy$70.00870.87% UpsideATHEAlterity Therapeutics 2.50Moderate Buy$12.00205.34% UpsideCHROChromocell Therapeutics 0.00N/AN/AN/AFGENFibroGen 2.50Moderate Buy$250.004,689.27% UpsideCurrent Analyst Ratings BreakdownLatest CHRO, FGEN, ALGS, and ATHE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$250.00 ➝ $250.004/1/2025FGENFibroGenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/31/2025ALGSAligos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALGSAligos Therapeutics$3.94M11.18N/AN/A($7.50) per share-0.96ATHEAlterity TherapeuticsN/AN/AN/AN/A$1.04 per shareN/ACHROChromocell TherapeuticsN/AN/AN/AN/A($1.65) per shareN/AFGENFibroGen$7.00M3.02N/AN/A($50.89) per share-0.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALGSAligos Therapeutics-$131.21M-$17.51N/AN/AN/A-1,628.75%14.67%7.19%8/5/2025 (Estimated)ATHEAlterity Therapeutics-$12.54MN/A0.00∞N/AN/AN/AN/A8/4/2025 (Estimated)CHROChromocell Therapeutics-$7.38M-$1.24N/A∞N/AN/AN/A-453.90%N/AFGENFibroGen-$47.58M-$2.50N/AN/AN/A-9.73%N/A-24.77%8/5/2025 (Estimated)Latest CHRO, FGEN, ALGS, and ATHE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025FGENFibroGen$0.75-$4.00-$4.75$0.05$2.00 million$2.70 million5/6/2025Q1 2025ALGSAligos Therapeutics-$2.80-$2.11+$0.69-$2.11$0.33 million$0.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALGSAligos TherapeuticsN/AN/AN/AN/AN/AATHEAlterity TherapeuticsN/AN/AN/AN/AN/ACHROChromocell TherapeuticsN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALGSAligos TherapeuticsN/A7.567.56ATHEAlterity TherapeuticsN/A3.84N/ACHROChromocell TherapeuticsN/A0.600.60FGENFibroGenN/A2.021.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALGSAligos Therapeutics60.43%ATHEAlterity Therapeutics2.14%CHROChromocell Therapeutics77.96%FGENFibroGen72.71%Insider OwnershipCompanyInsider OwnershipALGSAligos Therapeutics4.80%ATHEAlterity Therapeutics38.80%CHROChromocell Therapeutics16.40%FGENFibroGen3.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALGSAligos Therapeutics906.11 million5.82 millionNo DataATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableCHROChromocell Therapeutics46.60 million5.04 millionN/AFGENFibroGen5704.04 million3.96 millionOptionableCHRO, FGEN, ALGS, and ATHE HeadlinesRecent News About These CompaniesFibroGen Inc.June 24, 2025 | marketwatch.comFibroGen (NASDAQ:FGEN) Raised to "Hold" at Wall Street ZenJune 22, 2025 | americanbankingnews.comFibroGen (NASDAQ:FGEN) Trading Down 6.7% - What's Next?June 17, 2025 | marketbeat.comFibroGen To Implement 1-for-25 Reverse Stock SplitJune 14, 2025 | nasdaq.comFibroGen, Inc. Announces 1-for-25 Reverse Stock Split Effective June 16, 2025June 14, 2025 | nasdaq.comFibroGen Enters Relicensing Agreement with HiFiBiOJune 13, 2025 | marketwatch.comFibroGen Announces 1-for-25 Reverse Stock SplitJune 12, 2025 | globenewswire.comFibroGen, Inc. Appoints Dr. Michael Kauffman to Board of DirectorsJune 9, 2025 | quiverquant.comQFibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of DirectorsJune 9, 2025 | globenewswire.comFibroGen outlines $185M China divestiture and extended cash runway into 2027 while advancing prostate cancer pipelineMay 13, 2025 | msn.comFibroGen, Inc. (NASDAQ:FGEN) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comFibroGen, Inc.: FibroGen Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | finanznachrichten.deFibroGen, Inc. (FGEN) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comFibroGen (FGEN) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2025 | zacks.comFibroGen Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comA Preview Of FibroGen's EarningsMay 10, 2025 | benzinga.comDuchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)May 8, 2025 | globenewswire.comFibroGen, Inc. to Announce Q1 2025 Financial Results and Host Conference Call on May 12May 7, 2025 | nasdaq.comFibroGen to Report First Quarter 2025 Financial ResultsMay 5, 2025 | globenewswire.comWilliam Blair Keeps Their Hold Rating on FibroGen (FGEN)April 2, 2025 | markets.businessinsider.comFibroGen to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCHRO, FGEN, ALGS, and ATHE Company DescriptionsAligos Therapeutics NASDAQ:ALGS$7.21 +0.07 (+0.98%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$7.05 -0.16 (-2.23%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Alterity Therapeutics NASDAQ:ATHE$3.93 +0.01 (+0.26%) Closing price 06/27/2025 03:57 PM EasternExtended Trading$4.34 +0.41 (+10.43%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Chromocell Therapeutics NYSE:CHRO$1.35 +0.18 (+15.38%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.30 -0.05 (-3.33%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.FibroGen NASDAQ:FGEN$5.22 -0.08 (-1.51%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$5.43 +0.21 (+4.02%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
